Andrew Kasarskis | |
---|---|
Born | Madison, Wisconsin | November 2, 1972
Citizenship | American |
Alma mater | University of Kentucky University of California, Berkeley |
Scientific career | |
Fields | Bioinformatics, genomics |
Institutions | Sema4 |
Andrew Kasarskis (born November 2, 1972) is an American biologist. He is the Chief Data Officer (CDO) at Sema4. [1] He was previously CDO and an Executive Vice President (EVP) at the Mount Sinai Health System in New York City and, before that, vice chair of the Department of Genetics and Genomic Sciences and Co-director of the Icahn Institute for Genomics and Multiscale Biology at the Icahn School of Medicine at Mount Sinai. [2] Kasarskis is known for taking a network-based approach to biology and for directing the first medical school class offering students the opportunity to fully sequence and analyze their own genomes. [3]
Kasarskis completed bachelor's degrees in chemistry and biology at the University of Kentucky in 1992. In 1998, he completed his PhD in molecular and cell biology at the University of California, Berkeley, under the supervision of Kathryn Anderson. [2]
Throughout his career in industry and academia, Kasarskis' research has focused on the use of genetic and genomic data together with high-performance computing and advanced analytical tools to address biomedical needs and improve clinical treatment.
After completing his PhD in 1998, Kasarskis worked at Stanford University for two years, contributing to the development of various genome databases. In 2000, he entered industry, working in computational biology at DoubleTwist and later Rosetta Inpharmatics (acquired by Merck Research Laboratories). His work there centered on generating and mining complex biological data sets and using that information to build, predict, and model human disease. Kasarskis also worked for Sage Bionetworks and Pacific Biosciences before returning to academia. [4]
In 2011, Kasarskis became Vice Chair of the Department of Genetics and Genomic Sciences at the Icahn School of Medicine at Mount Sinai and Co-director, along with Eric Schadt, of the Icahn Institute for Genomics and Multiscale Biology, where Kasarskis's research focuses on improving health outcomes through better data mining, and his research program includes sequencing-based pathogen surveillance; pharmacogenomics; electronic health records; and systems biology of sleep, behavior, and stress. [2] In 2019, Kasarskis was appointed Chief Data Officer and Executive Vice President of Mount Sinai Health System, [5] where he leads efforts to improve clinical data infrastructure [6] and leverage data to improve patient outcomes while accelerating research and innovation. [7] [8]
Kasarskis is known for directing the first graduate course that allowed medical and PhD students to fully sequence and analyze their own genomes, along with co-instructors Michael Linderman, George Diaz, Ali Bashir, and Randi Zinberg. He has said that courses like this will be critical for training teams of people capable of performing this type of analysis in a medical setting. He chose whole genome sequencing because he expects the more limited exome sequencing will not be a relevant technological approach in the long term. [3]
Kasarskis has called for improvements to informed consent protocols in patient research based on the concept that studies involving DNA cannot fully be made anonymous. He was quoted in the journal Nature saying, "We need to move beyond an assumption that you cannot be identified from the data that exist about you and really work to make sure that we're protecting people's rights in ways that allow us to use the data that are out there for individuals' and researchers' benefit." [9]
In 2019, Kasarskis joined a five-year collaborative study with Mount Sinai Health System, Sanofi, and Sema4, aimed to provide insights into the biological mechanisms of asthma using diverse data sets such as clinical data, genomics, immunological environmental, and sensor data from devices to carryout advanced network modeling of the disease. Kasarskis reported that understanding the molecular basis of clinical subtypes of asthma in the study would enable better management of asthma and could provide opportunities to discover new treatments for the disease. [10]
In 2020, the molecular pathogen surveillance program Kasarskis had established with Dr. Harm van Bakel and others at the Mount Sinai Health System clearly demonstrated that SARS-CoV2, the virus causing COVID-19, was introduced to the New York Metropolitan Area not from Asia but predominately from Europe, with some contribution from other United States regions. [11] The ensuing research paper was published in the journal Science. [12]
Bioinformatics is an interdisciplinary field that develops methods and software tools for understanding biological data, in particular when the data sets are large and complex. As an interdisciplinary field of science, bioinformatics combines biology, chemistry, physics, computer science, information engineering, mathematics and statistics to analyze and interpret the biological data. Bioinformatics has been used for in silico analyses of biological queries using computational and statistical techniques.
Genomics is an interdisciplinary field of biology focusing on the structure, function, evolution, mapping, and editing of genomes. A genome is an organism's complete set of DNA, including all of its genes as well as its hierarchical, three-dimensional structural configuration. In contrast to genetics, which refers to the study of individual genes and their roles in inheritance, genomics aims at the collective characterization and quantification of all of an organism's genes, their interrelations and influence on the organism. Genes may direct the production of proteins with the assistance of enzymes and messenger molecules. In turn, proteins make up body structures such as organs and tissues as well as control chemical reactions and carry signals between cells. Genomics also involves the sequencing and analysis of genomes through uses of high throughput DNA sequencing and bioinformatics to assemble and analyze the function and structure of entire genomes. Advances in genomics have triggered a revolution in discovery-based research and systems biology to facilitate understanding of even the most complex biological systems such as the brain.
DNA sequencing is the process of determining the nucleic acid sequence – the order of nucleotides in DNA. It includes any method or technology that is used to determine the order of the four bases: adenine, guanine, cytosine, and thymine. The advent of rapid DNA sequencing methods has greatly accelerated biological and medical research and discovery.
Personal genomics or consumer genetics is the branch of genomics concerned with the sequencing, analysis and interpretation of the genome of an individual. The genotyping stage employs different techniques, including single-nucleotide polymorphism (SNP) analysis chips, or partial or full genome sequencing. Once the genotypes are known, the individual's variations can be compared with the published literature to determine likelihood of trait expression, ancestry inference and disease risk.
Whole genome sequencing (WGS), also known as full genome sequencing, complete genome sequencing, or entire genome sequencing, is the process of determining the entirety, or nearly the entirety, of the DNA sequence of an organism's genome at a single time. This entails sequencing all of an organism's chromosomal DNA as well as DNA contained in the mitochondria and, for plants, in the chloroplast.
CSIR Institute of Genomics and Integrative Biology (CSIR-IGIB) is a scientific research institute devoted primarily to biological research. It is a part of Council of Scientific and Industrial Research (CSIR), India.
Exome sequencing, also known as whole exome sequencing (WES), is a genomic technique for sequencing all of the protein-coding regions of genes in a genome. It consists of two steps: the first step is to select only the subset of DNA that encodes proteins. These regions are known as exons—humans have about 180,000 exons, constituting about 1% of the human genome, or approximately 30 million base pairs. The second step is to sequence the exonic DNA using any high-throughput DNA sequencing technology.
Pacific Biosciences of California, Inc. is an American biotechnology company founded in 2004 that develops and manufactures systems for gene sequencing and some novel real time biological observation. PacBio describes its platform as single-molecule real-time sequencing (SMRT), based on the properties of zero-mode waveguides.
John Quackenbush is an American computational biologist and genome scientist. He is a professor of biostatistics and computational biology and a professor of cancer biology at the Dana-Farber Cancer Institute (DFCI), as well as the director of its Center for Cancer Computational Biology (CCCB). Quackenbush also holds an appointment as a professor of computational biology and bioinformatics in the Department of Biostatistics at the Harvard School of Public Health (HSPH).
Translational bioinformatics (TBI) is an emerging field in the study of health informatics, focused on the convergence of molecular bioinformatics, biostatistics, statistical genetics and clinical informatics. Its focus is on applying informatics methodology to the increasing amount of biomedical and genomic data to formulate knowledge and medical tools, which can be utilized by scientists, clinicians, and patients. Furthermore, it involves applying biomedical research to improve human health through the use of computer-based information system. TBI employs data mining and analyzing biomedical informatics in order to generate clinical knowledge for application. Clinical knowledge includes finding similarities in patient populations, interpreting biological information to suggest therapy treatments and predict health outcomes.
Eric Emil Schadt is an American mathematician and computational biologist. He is founder and chief executive officer of Sema4, a patient-centered health intelligence company, and dean for precision medicine and Mount Sinai Professor in Predictive Health and Computational Biology at the Icahn School of Medicine at Mount Sinai. He was previously founding director of the Icahn Institute for Genomics and Multiscale Biology and chair of the Department of Genetics and Genomics Sciences at the Icahn School of Medicine at Mount Sinai.
Dr. Vinod Scaria FRSB, FRSPH is an Indian biologist, medical researcher pioneering in Precision Medicine and Clinical Genomics in India. He is best known for sequencing the first Indian genome. He was also instrumental in the sequencing of The first Sri Lankan Genome, analysis of the first Malaysian Genome sequencing and analysis of the Wild-type strain of Zebrafish and the IndiGen programme on Genomics for Public Health in India
The Icahn Genomics Institute is a biomedical and genomics research institute located in New York, NY. It is housed within the Icahn School of Medicine at Mount Sinai. Its aim is to establish a new generation of medicines that can better treat diseases afflicting the world, including cancer, heart disease and infectious pathogens. To do this, the institute’s doctors and scientists are developing and employing new types of treatments that utilize DNA and RNA based therapies, such as CRISPR, siRNA, RNA vaccines, and CAR T cells, and searching for novel drug targets through the use of functional genomics and data science.
Ethylin Wang Jabs is a Chinese-American physician-scientist with expertise in medical genetics, pediatrics, and craniofacial biology. She is currently vice chair of the Department of Genetics and Genomic Sciences at the Icahn School of Medicine at Mount Sinai Medical Center. Jabs is also a professor in the departments of developmental and regenerative biology and pediatrics at Mount Sinai and an adjunct professor in pediatrics, medicine, and surgery at the Johns Hopkins School of Medicine. Her research and clinical practice have focused on development genetics and patients with birth defects.
Joseph D. Buxbaum is an American molecular and cellular neuroscientist, autism researcher, and the Director of the Seaver Autism Center at the Icahn School of Medicine at Mount Sinai. Buxbaum is also, along with Simon Baron-Cohen, the co-editor of the BioMed Central journal Molecular Autism, and is a member of the scientific advisory board of the Autism Science Foundation. Buxbaum is a Professor of Psychiatry, Neuroscience, and Genetics and Genomic Sciences. He is also the Vice Chair for Research and for Mentoring in the Department of Psychiatry at the Icahn School of Medicine at Mount Sinai.
Joel Dudley is currently Associate Professor of Genetics and Genomic Sciences and founding Director of the Institute for Next Generation Healthcare at the Icahn School of Medicine at Mount Sinai. In March, 2018 Dr. Dudley was named Executive Vice President for Precision Health for the Mount Sinai Health System (MSHS). In 2017 he was awarded an Endowed Professorship by Mount Sinai in Biomedical Data Science. Prior to Mount Sinai, he held positions as Co-founder and Director of Informatics at NuMedii, Inc. and Consulting Professor of Systems Medicine in the Department of Pediatrics at Stanford University School of Medicine. His work is focused at the nexus of -omics, digital health, artificial intelligence (AI), scientific wellness, and healthcare delivery. His work has been featured in the Wall Street Journal, Scientific American, MIT Technology Review, CNBC, and other popular media outlets. He was named in 2014 as one of the 100 most creative people in business by Fast Company magazine. He is co-author of the book Exploring Personal Genomics from Oxford University Press. Dr. Dudley received a BS in Microbiology from Arizona State University and an MS and PhD in Biomedical Informatics from Stanford University School of Medicine.
Alicia Yinema Kate Nungarai Oshlack is an Australian bioinformatician and is Co-Head of Computational Biology at the Peter MacCallum Cancer Centre in Melbourne, Victoria, Australia. She is best known for her work developing methods for the analysis of transcriptome data as a measure of gene expression. She has characterized the role of gene expression in human evolution by comparisons of humans, chimpanzees, orangutans, and rhesus macaques, and works collaboratively in data analysis to improve the use of clinical sequencing of RNA samples by RNAseq for human disease diagnosis.
Multiomics, multi-omics, integrative omics, "panomics" or "pan-omics" is a biological analysis approach in which the data sets are multiple "omes", such as the genome, proteome, transcriptome, epigenome, metabolome, and microbiome ; in other words, the use of multiple omics technologies to study life in a concerted way. By combining these "omes", scientists can analyze complex biological big data to find novel associations between biological entities, pinpoint relevant biomarkers and build elaborate markers of disease and physiology. In doing so, multiomics integrates diverse omics data to find a coherently matching geno-pheno-envirotype relationship or association. The OmicTools service lists more than 99 softwares related to multiomic data analysis, as well as more than 99 databases on the topic.
The Resilience Project is a project, undertaken by the Icahn School of Medicine at Mount Sinai in collaboration with Sage Bionetworks.
Personalized onco-genomics (POG) is the field of oncology and genomics that is focused on using whole genome analysis to make personalized clinical treatment decisions. The program was devised at British Columbia's BC Cancer Agency and is currently being led by Marco Marra and Janessa Laskin. Genome instability has been identified as one of the underlying hallmarks of cancer. The genetic diversity of cancer cells promotes multiple other cancer hallmark functions that help them survive in their microenvironment and eventually metastasise. The pronounced genomic heterogeneity of tumours has led researchers to develop an approach that assesses each individual's cancer to identify targeted therapies that can halt cancer growth. Identification of these "drivers" and corresponding medications used to possibly halt these pathways are important in cancer treatment.